Literature DB >> 20153646

Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells.

Soo Jeong Choi1, Myoung Ju Moon, So Deok Lee, Sang-Un Choi, Sun-Young Han, Yong-Chul Kim.   

Abstract

Indirubin derivatives were identified as potent FLT3 tyrosine kinase inhibitors with anti-proliferative activity at acute myeloid leukemic cell lines, RS4;11 and MV4;11 which express FLT3-WT and FLT3-ITD mutation, respectively. Among several 5 and 5'-substituted indirubin derivatives, 5-fluoro analog, 13 exhibited potent inhibitory activity at FLT3 (IC(50)=15 nM) with more than 100-fold selectivity versus 6 other kinases and potent anti-proliferative effect for MV4;11 cells (IC(50)=72 nM) with 30-fold selectivity versus RS4;11 cells. Cell cycle analysis indicated that compound 13 induced cell cycle arrest at G(0)/G(1) phase in MV4;11 cells. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20153646     DOI: 10.1016/j.bmcl.2010.01.039

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  9 in total

1.  Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines.

Authors:  Nicolas Gaboriaud-Kolar; Vasillios Myrianthopoulos; Konstantina Vougogiannopoulou; Panagiotis Gerolymatos; David A Horne; Richard Jove; Emmanuel Mikros; Sangkil Nam; Alexios-Leandros Skaltsounis
Journal:  J Nat Prod       Date:  2016-10-11       Impact factor: 4.803

Review 2.  Are the Traditional Medical Uses of Muricidae Molluscs Substantiated by Their Pharmacological Properties and Bioactive Compounds?

Authors:  Kirsten Benkendorff; David Rudd; Bijayalakshmi Devi Nongmaithem; Lei Liu; Fiona Young; Vicki Edwards; Cathy Avila; Catherine A Abbott
Journal:  Mar Drugs       Date:  2015-08-18       Impact factor: 5.118

3.  The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

4.  Enhancing effects of indirubin on the arsenic disulfide-induced apoptosis of human diffuse large B-cell lymphoma cells.

Authors:  Ling Wang; Xianglu Li; Xinyu Liu; Kang Lu; N A Chen; Peipei Li; Xiao Lv; Xin Wang
Journal:  Oncol Lett       Date:  2015-02-09       Impact factor: 2.967

5.  Development of UHPLC-MS/MS Method for Indirubin-3'-Oxime Derivative as a Novel FLT3 Inhibitor and Pharmacokinetic Study in Rats.

Authors:  Na Yoon Kim; Yong-Chul Kim; Yoon Gyoon Kim
Journal:  Molecules       Date:  2020-04-27       Impact factor: 4.411

Review 6.  Molluscan Compounds Provide Drug Leads for the Treatment and Prevention of Respiratory Disease.

Authors:  Kate Summer; Jessica Browne; Lei Liu; Kirsten Benkendorff
Journal:  Mar Drugs       Date:  2020-11-19       Impact factor: 5.118

Review 7.  Oximes: Novel Therapeutics with Anticancer and Anti-Inflammatory Potential.

Authors:  Igor A Schepetkin; Mark B Plotnikov; Andrei I Khlebnikov; Tatiana M Plotnikova; Mark T Quinn
Journal:  Biomolecules       Date:  2021-05-22

8.  In silico molecular comparisons of C. elegans and mammalian pharmacology identify distinct targets that regulate feeding.

Authors:  George A Lemieux; Michael J Keiser; Maria F Sassano; Christian Laggner; Fahima Mayer; Roland J Bainton; Zena Werb; Bryan L Roth; Brian K Shoichet; Kaveh Ashrafi
Journal:  PLoS Biol       Date:  2013-11-19       Impact factor: 8.029

9.  Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia.

Authors:  Hyo Jeong Lee; Jungeun Lee; Pyeonghwa Jeong; Jungil Choi; Juhwa Baek; Su Jin Ahn; Yeongyu Moon; Jeong Doo Heo; Young Hee Choi; Young-Won Chin; Yong-Chul Kim; Sun-Young Han
Journal:  Oncotarget       Date:  2017-12-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.